Literature DB >> 1955097

Acute insulin response to intravenous glucose, glucagon and arginine in some subjects at risk for type 1 (insulin-dependent) diabetes mellitus.

S Bardet1, V Rohmer, D Maugendre, M Marre, G Semana, J M Limal, H Allannic, B Charbonnel, P Saï.   

Abstract

The relationships between first-phase insulin secretion to i.v. glucagon and i.v. arginine were studied in 19 healthy adult volunteers (Group I) and in 21 subjects at risk for Type 1 (insulin-dependent) diabetes mellitus with either a "normal" (n = 11; Group IIa) or a "low" insulin response to i.v. glucose (n = 10; Group IIb). Groups I and IIa displayed similar insulin responses to the three secretagogues. In contrast, Group IIb demonstrated lower insulin responses to both glucagon and arginine than control subjects (p less than 0.007 and p less than 0.04 respectively) or than "normo-responders" to glucose (p less than 0.007 and p less than 0.04 respectively). In Group IIb however, arginine-stimulated insulin release was increased compared to the response to glucose (p less than 0.006), while glucagon and glucose led to non-statistically different responses. Five "low-responders" developed Type 1 diabetes. As a group, they displayed lower responses to glucagon and to arginine than subjects who up to now have not developed the disease (p less than 0.05 and p less than 0.0003 respectively). In the subjects who progressed to diabetes, the responses to glucose and glucagon were similarly blunted. In the "low-responders" who have not developed the disease, no statistical difference could be detected between mean responses to glucagon and glucose, but four out of these five subjects had a glucagon-stimulated response within the control range and higher than their corresponding response to glucose. Arginine led to a higher stimulation than glucose, in subgroups that either progressed to diabetes (p less than 0.006) or did not (p less than 0.002).(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1955097     DOI: 10.1007/bf00400994

Source DB:  PubMed          Journal:  Diabetologia        ISSN: 0012-186X            Impact factor:   10.122


  27 in total

1.  Inhibition of glucose transport into rat islet cells by immunoglobulins from patients with new-onset insulin-dependent diabetes mellitus.

Authors:  J H Johnson; B P Crider; K McCorkle; M Alford; R H Unger
Journal:  N Engl J Med       Date:  1990-03-08       Impact factor: 91.245

2.  The pattern of basal and stimulated insulin responses to intravenous glucose in first degree relatives of type 1 (insulin-dependent) diabetic children and unrelated adults aged 5 to 50 years.

Authors:  C P Smith; A J Williams; J M Thomas; H R Archibald; V D Algar; G F Bottazzo; E A Gale; M O Savage
Journal:  Diabetologia       Date:  1988-07       Impact factor: 10.122

3.  Life-table analysis of progression to diabetes of anti-insulin autoantibody-positive relatives of individuals with type I diabetes.

Authors:  A G Ziegler; R Ziegler; P Vardi; R A Jackson; J S Soeldner; G S Eisenbarth
Journal:  Diabetes       Date:  1989-10       Impact factor: 9.461

4.  Reproducibility of beta-cell function estimates in non-insulin-dependent diabetes mellitus.

Authors:  H J Gjessing; E M Damsgaard; L E Matzen; A Frøland; O K Faber
Journal:  Diabetes Care       Date:  1987 Sep-Oct       Impact factor: 19.112

Review 5.  Multiple target antigens in pre-type I diabetes: implications for prediction.

Authors:  R Ziegler; G S Eisenbarth
Journal:  Horm Res       Date:  1990

6.  Nonprogression of subclinical beta-cell dysfunction among first-degree relatives of IDDM patients. 5-yr follow-up of the Seattle Family Study.

Authors:  D K McCulloch; L J Klaff; S E Kahn; S L Schoenfeld; C J Greenbaum; R S Mauseth; E A Benson; G T Nepom; L Shewey; J P Palmer
Journal:  Diabetes       Date:  1990-05       Impact factor: 9.461

7.  Differential sensitivity to beta-cell secretagogues in "early," type I diabetes mellitus.

Authors:  O P Ganda; S Srikanta; S J Brink; M A Morris; R E Gleason; J S Soeldner; G S Eisenbarth
Journal:  Diabetes       Date:  1984-06       Impact factor: 9.461

8.  Arginine-stimulated acute phase of insulin and glucagon secretion in diabetic subjects.

Authors:  J P Palmer; J W Benson; R M Walter; J W Ensinck
Journal:  J Clin Invest       Date:  1976-09       Impact factor: 14.808

9.  Antibodies to a 64,000 Mr human islet cell antigen precede the clinical onset of insulin-dependent diabetes.

Authors:  S Baekkeskov; M Landin; J K Kristensen; S Srikanta; G J Bruining; T Mandrup-Poulsen; C de Beaufort; J S Soeldner; G Eisenbarth; F Lindgren
Journal:  J Clin Invest       Date:  1987-03       Impact factor: 14.808

10.  Quantification of islet-cell antibodies and prediction of insulin-dependent diabetes.

Authors:  E Bonifacio; P J Bingley; M Shattock; B M Dean; D Dunger; E A Gale; G F Bottazzo
Journal:  Lancet       Date:  1990-01-20       Impact factor: 79.321

View more
  6 in total

1.  Autoantibodies in recent onset type-1 diabetic patients to a Mr 60K microsomal hepatic protein: new evidence for autoantibodies to the type-2 glucose transporter.

Authors:  M Pehuet-Figoni; F Alvarez; J F Bach; L Chatenoud
Journal:  Clin Exp Immunol       Date:  2000-11       Impact factor: 4.330

2.  Altered islet beta-cell function before the onset of type 1 (insulin-dependent) diabetes mellitus.

Authors:  S S Lo; M Hawa; S F Beer; D A Pyke; R D Leslie
Journal:  Diabetologia       Date:  1992-03       Impact factor: 10.122

3.  Early metabolic markers of islet allograft dysfunction.

Authors:  David A Baidal; Raquel N Faradji; Shari Messinger; Tatiana Froud; Kathy Monroy; Camillo Ricordi; Rodolfo Alejandro
Journal:  Transplantation       Date:  2009-03-15       Impact factor: 4.939

4.  Quantification of human cytoplasmic islet-cell antibodies which cross-react with mouse pancreas: a follow-up study in type 1 (insulin-dependent) diabetic patients and in first-degree relatives.

Authors:  P Saï; A Elmansour; M Audrain; B Charbonnel; S Bardet
Journal:  Diabetologia       Date:  1993-08       Impact factor: 10.122

5.  Combined analysis of islet cell antibodies which cross-react with mouse pancreas, antibodies to the M(r) 64,000 islet protein, and antibodies to glutamate decarboxylase in subjects at risk for IDDM.

Authors:  L Chaillous; M Delamaire; A Elmansour; D Maugendre; V Rohmer; M G Joseph; P Lecomte; J M Limal; B Charbonnel; H Allannic
Journal:  Diabetologia       Date:  1994-05       Impact factor: 10.122

6.  Human pancreatic islet function at the onset of type 1 (insulin-dependent) diabetes mellitus.

Authors:  I Conget; J Fernández-Alvarez; J Ferrer; Y Sarri; A Novials; N Somoza; R Pujol-Borrell; R Casamitjana; R Gomis
Journal:  Diabetologia       Date:  1993-04       Impact factor: 10.122

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.